Skip to main content

Table 1 General characteristics of patients

From: Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer

  No adjuvant therapy (n = 59) Platinum-based chemotherapy (n = 60) p value
Age (years) 64.14 ± 12.75 59.80 ± 9.70 0.027
Male 36 (61.0%) 37 (61.7%) 0.546
FEV1 (liters) 90.10 ± 25.99 97.91 ± 25.40 0.1
Comorbidity 38 (64.4%) 33 (55.0%) 0.352
Type of operation    0.489
  Lobectomy 54 (91.5%) 56 (93.3%)  
  Pneumonectomy 5 (8.5%) 4 (6.7%)  
Dissected lymph nodes 22.88 ± 9.21 28.08 ± 13.08 0.017
Tumor size (mm) 28.35 ± 9.74 33.80 ± 9.82 0.003
Pathology    0.295
  Adenocarcinoma 27 (45.8%) 36 (60.0%)  
  Squamous cell carcinoma 18 (30.5%) 14 (23.3%)  
  Others 14 (23.7%) 10 (16.7%)  
Differentiation    0.306
  Well 17 (28.8%) 12 (20.0%)  
  Moderate to poor 37 (62.7%) 39 (65.0%)  
  Not defined 5 (8.5%) 9 (15.0%)  
Lymphovascular invasion 8 (13.6%) 11 (18.3%) 0.323
Pleural invasion    0.428
  pl0 34 (57.6%) 28 (46.7%)  
  pl1 15 (25.4%) 17 (28.3%)  
  pl2 10 (16.9%) 15 (25.0%)  
Performance status (ECOG)    0.004
  0 36 (61.0%) 52 (86.7%)  
  1 20 (33.9%) 8 (13.3%)  
  2 3 (5.1%) 0